As Janssen Biotech Inc. and Tesaro Inc. announced a licensing deal for the experimental prostate cancer drug, PARP inhibitor niraparib, researchers reported on unexpected effects of androgen deprivation therapy, which continues to be the mainstay of prostate cancer treatment.